

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Date Submitted: January 16, 2009

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	10/706,328
Filing Date	11/12/2003
First Named Inventor	Alison Hannah
Art Unit	1614
Examiner Name	James D. Anderson
Attorney Docket Number	072121-0366 (19993.0005)

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		2003/0087854	05-08-2003	Monia et al.	
		2005/0261307	11-24-2005	Cai et al.	
		3,663,606	05-16-1972	Yoshikazu Isowa	
		5,151,360	09-29-1992	Handa et al.	
		6,111,110	08-29-2000	Brennan et al.	
		6,137,010	10-24-2000	Joo et al.	
		6,174,912	01-16-2001	Beck et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
		WO 01/74296	10-11-2001	Witte et al.		
		WO 2005/082340	09-09-2005	Chiron Corporation		
		JP 59-130284 and English Abstract	07-26-1984	Bayer AG		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		BASTIN et al. "Salt selection and Optimisation procedures for pharmaceutical new chemical entities, organic process research & development 2000, 4, 427-35.	
		BECK, J. R., "A Direct Synthesis of Benzo[b]thiophene-2-carboxylate Esters Involving Nitro Displacement," <i>J. Org. Chem.</i> , Vol. 37, No. 21, 1972, pp. 3224-3226.	
		International Search Report for PCT/US06/19349 dated September 11, 2006.	
		KREIMEYER, A. et al., "Evaluation and Biological Properties of Reactive Ligands for the Mapping of the Glycine Site on the N-Methyl-D-aspartate (NMDA) Receptor," <i>J. Med. Chem.</i> , Vol. 42, 1999, pp. 4394-4404; published by American Chemical Society.	
		WINSTEAD, E., "p53 Gene May Help Fight Tumors," <i>NCI Cancer Bulletin</i> , Vol. 4, No. 5, pp. 1-2, 2007.	
		YAO et al., "Cell-specific but p53-independent Regulation of Vascular Endothelial Growth Factor Expression by Interferons in Human Glioblastoma Cells," <i>Journal of Neuro-Oncology</i> , Vol. 76, pp. 219-225, 2006.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

MADI_1592731.1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JDA/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Date Submitted: January 16, 2009

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	10/706,328
Filing Date	11/12/2003
First Named Inventor	Alison Hannah
Art Unit	1614
Examiner Name	James D. Anderson
Attorney Docket Number	072121-0366 (19993.0005)

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		YOO, et al., "Synchronous Elevation of Soluble Intercellular Adhesion Molecule-1 (ICAM-1) and Vascular Cell Adhesion Molecule-1 (VCAM-1) Correlates with Gastric Cancer Progression," <i>Yonsei Medical Journal</i> , Vol. 39, No. 1, pp. 27-36, 1998.	
		ZENG et al., "HDAC3 is crucial in shear- and VEGF-induced stem cell differentiation toward endothelial cells," <i>The Journal of Cell Biology</i> , Vol. 174, No. 7, pp. 1059-1069, 2006.	

Examiner
Signature

/James Anderson/

Date
Considered

04/23/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

MADI_1592731.1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JDA/